Immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.
Future Oncol
; 17(33): 4447-4456, 2021 Nov.
Article
in English
| MEDLINE | ID: covidwho-1338142
ABSTRACT
Aim:
To evaluate the immunogenicity and safety of the CoronaVac vaccine in patients with cancer receiving active systemic therapy.Methods:
This multicenter, prospective, observational study was conducted with 47 patients receiving active systemic therapy for cancer. CoronaVac was administered as two doses (3 µg/day) on days 0 and 28. Antibody level higher than 1 IU/ml was defined as 'immunogenicity.'Results:
The immunogenicity rate was 63.8% (30/47) in the entire patient group, 59.5% (25/42) in those receiving at least one cytotoxic drug and 100% (five of five) in those receiving monoclonal antibody or immunotherapy alone. Age was an independent predictive factor for immunogenicity (odds ratio 0.830; p = 0.043).Conclusion:
More than half of cancer patients receiving active systemic therapy developed immunogenicity.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Vaccines
/
SARS-CoV-2
/
COVID-19
/
Neoplasms
/
Antineoplastic Agents
Type of study:
Cohort study
/
Experimental Studies
/
Observational study
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
English
Journal:
Future Oncol
Year:
2021
Document Type:
Article
Affiliation country:
Fon-2021-0597
Similar
MEDLINE
...
LILACS
LIS